オランザピン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H315：皮膚刺激

  H319：強い眼刺激

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

  P332+P313：皮膚刺激が生じた場合：医師の診断/手当てを受けるこ と。

  P337+P313：眼の刺激が続く場合：医師の診断/手当てを受けること。

オランザピン 価格

MSDS Information

• 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine

オランザピン 化学特性,用途語,生産方法

• 外観

  うすい黄色〜褐色, 結晶〜粉末

• 溶解性

  アセトニトリルに可溶

• 用途

  ドーパミン、セロトニン受容 体をはじめ、多数の神経物質受容体に対する 拮抗作用を示します。

• 用途

  ドパミン、セロトニン受容体 をはじめ、多数の神経物質受容体に対する拮 抗作用を示します。

• 効能

  統合失調症治療薬

• 商品名

  オランザピン (ニプロ); ジプレキサ (日本イーライリリー); ジプレキサ (日本イーライリリー); ジプレキサ (日本イーライリリー); ジプレキサ (日本イーライリリー)

• 説明

  Zyprexa was launched in Canada, Germany, the UK and US as an antipsychotic agent. Prepared in three steps via the intermediate diazepinone, it is an atypical antipsychotic with a high affinity for dopaminergic and serotonergic receptors. Specifically, olazapine is a potent 5-HT₂/D₂ antagonist with anticholinergic activity. It has a greater antagonistic effect at 5-HT_2a than at dopamine D₂ receptors and in vivo is clozapine-like. Thus it is less likely to produce extrapyramidal side effects and does not produce any granulocytopenia. Its 10 metabolic products are all inactive.

• 化学的特性

  Yellow Crystalline Powder

• 使用

  A serotonin (5-HT2) and dopamine (D1/D2) receptor antagonist with anticholinergic activity. Antipsychotic.

• 定義

  ChEBI: A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.

• 一般的な説明

  Olanzapine, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Zyprexa), isa yellow crystalline solid that is essentially insoluble in water.Olanzapine orally disintegrating tablets (Zyprexa Zydis) is asolid dosage form that immediately disintegrates when exposedto saliva. This product is useful for elderly patients whohave difficulty in swallowing. An injectable form, olanzapinefor injection (Zyprexa IM), is indicated for agitation associatedwith schizophrenia or bipolar I mania. Olanzapine iscombined with fluoxetine (Symbyax) for use in depressionthat is associated with bipolar I disorder. Peak concentrationsof oral olanzapine are reached at 6 hours after oral administration,and absorption of the compound is not affected byfood.
  Olanzapine binds with high affinity at DA D₂, 5-HT_2A,5-HT_2C, 5-HT₆,α1, and H₁ histamine receptors. The effectsof olanzapine for the treatment of schizophrenia are presumablymediated through antagonism at D₂ and 5-HT_2Areceptors.The use of olanzapine in acute maniathat is associated with bipolar I disorder is thought to bemediated by antagonism at D₂ and other monamine receptors.Additionally, olanzapine is postulated to produce itsmood stabilizing and antidepressant effects through 5-HT_2Areceptor blockade and increased cortical DA and NE concentrations.Several studies have investigated the effectof olanzapine-induced weight gain and new-onset type 2diabetes.In a comparison study with risperidone,olanzapine was shown to have a greater risk of producingdyslipidemia and type 2 diabetes.

• 臨床応用

  The thienobenzodiazepine olanzapine is an effective atypical antipsychotic agent that is close in structure to clozapine but has a somewhat different neuropharmacological profile, in that it is a more potent antagonist at dopamine D2 and, especially, serotonin 5-HT2A receptors. Olanzapine is well absorbed after oral administration and is metabolized mainly by CYP1A2 to inactive metabolites, with a variable half-life of approximately 20 to 50 hours.

オランザピン 上流と下流の製品情報

オランザピン 生産企業

Global(549)Suppliers

オランザピン スペクトルデータ(¹HNMR)

132539-06-1, オランザピン キーワード